MADRIGAL PHARMACEUTICALS, INC. (MDGL) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | |
| Borrowing debt due after one year | 340.79M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 838.75M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Total assets | 1.24B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $340.79M | (m) | $838.75M | $1.24B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $340.33M | (m) | $812.77M | $1.23B | (m) |
| 2025-12-31 | (m) | (m) | (m) | $339.88M | (m) | $983.56M | $1.26B | (m) |
| 2025-09-30 | (m) | (m) | (m) | $339.75M | (m) | $1.11B | $1.36B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $118.38M | (m) | $797.02M | $1.02B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $118.00M | (m) | $843.07M | $996.63M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $117.57M | (m) | $926.25M | $1.04B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $117.09M | (m) | $998.63M | $1.07B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $116.61M | (m) | $1.06B | $1.10B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $116.14M | (m) | $1.06B | $1.08B | (m) |
| 2023-12-31 | (m) | (m) | (m) | $115.48M | (m) | $634.13M | $640.55M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $114.73M | (m) | $232.35M | $237.96M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $99.25M | (m) | $298.42M | $302.46M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $83.97M | (m) | $329.48M | $332.45M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $49.29M | (m) | $358.77M | $362.57M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $48.98M | (m) | $153.19M | $158.64M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $48.67M | (m) | $211.77M | $216.39M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $0.00 | (m) | $270.35M | $273.33M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |